tirzepatide compound court case FDA Update: Current Guidelines for Semaglutide and Compounding Lilly Statement on Mounjaro® (tirzepatide)

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of obesity in adults, is an effective weight-loss drug in teenagers, according to results from the STEP TEENS study

PMCID: PMC8478295

I feel healthier, happier, and more in control of my diabetes. B Bonnie Verified patient Finger pricks dailynone See if you qualify for our weight loss or diabetes monitoring programs $50/month copay with Medicare for those who qualify Medicare GLP-1 Bridge Program Brand-name GLP-1 medication through Medicare's new Bridge Program we check your eligibility for free

Semaglutide : Although highly effective, Semaglutide treatments can be costly, especially for long-term use

Despite the chronic nature of obesity and its need for long-term management, treatment options remain limited